The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer.

The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer.
复制标题

新型 VEGF 受体 2 抑制剂 YLL545 抑制乳腺癌血管生成和生长

DOI:
10.18632/oncotarget.9392
复制
发表时间:
2016-07-05
期刊:
影响因子:
--
通讯作者:
Xiang R
Xiang R
中科院分区:
其他
文献类型:
--
作者:
Zhang J;Liu C;Shi W;Yang L;Zhang Q;Cui J;Fang Y;Li Y;Ren G;Yang S;Xiang R

文献摘要

参考文献

被引文献

相似文献

它们的抗血管生成作用使得血管内皮生长因子受体2(VEGFR 2)抑制剂可用于癌症治疗。然而,这些药物中的大多数都有意想不到的副作用。在这里,我们发现新型VEGFR 2抑制剂YLL 545抑制了三阴性乳腺癌的肿瘤血管生成和生长,而没有副作用。YLL 545处理还显著抑制体外人脐血管内皮细胞(HUVECs)的增殖、迁移、侵袭和管形成。YLL 545的这些作用等于或大于索拉非尼的作用。此外,YLL 545抑制VEGF诱导的VEGFR 2磷酸化和下游信号调节因子的激活,例如HUVEC中的磷酸化-STAT 3和磷酸化-ERK 1/2。斑马鱼中的胚胎血管生成测定和小鼠中的Matrigel栓测定证明YLL 545抑制体内血管生成。YLL 545还在体外和体内抑制MDA-MB-231乳腺癌细胞的增殖并诱导凋亡,并且50 mg/kg/d YLL 545在BALB/c裸鼠中抑制超过50%的人肿瘤异种移植物生长。这些观察结果表明YLL 545是一种潜在有用的抗癌候选药物。
Their antiangiogenic effects make vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors useful for cancer treatment. However, most of these drugs have unexpected adverse side effects. Here, we show that the novel VEGFR2 inhibitor YLL545 suppressed tumor angiogenesis and growth in triple-negative breast cancer without adverse effects. YLL545 treatment also markedly inhibited proliferation, migration, invasion, and tube formation by human umbilical vascular endothelial cells (HUVECs) in vitro. These effects of YLL545 were equal to or greater than those seen with sorafenib. In addition, YLL545 inhibited VEGF-induced phosphorylation of VEGFR2 and activation of downstream signaling regulators, such as phospho-STAT3 and phospho-ERK1/2, in HUVECs. Embryonic angiogenesis assays in zebrafish and Matrigel plug assays in mice demonstrated that YLL545 inhibits angiogenesis in vivo. YLL545 also inhibited proliferation and induced apoptosis in MDA-MB-231 breast cancer cells both in vitro and in vivo, and 50 mg/kg/d YLL545 inhibited human tumor xenograft growth by more than 50% in BALB/c nude mice. These observations suggest YLL545 is a potentially useful anticancer drug candidate.
DOI: 10.1016/s0049-3848(10)70014-1
发表时间: 2010-04-01
影响因子: 7.5
作者:
Elice, F.;Rodeghiero, F.
通讯作者: Rodeghiero, F.
DOI: 10.18632/oncotarget.188
发表时间: 2010-11
期刊: Oncotarget
影响因子: --
作者:
Markman B;Dienstmann R;Tabernero J
通讯作者: Tabernero J
DOI: 10.1074/jbc.m111.260133
发表时间: 2011-08-26
影响因子: 4.8
作者:
Castonguay, Roselyne;Werner, Eric D.;Grinberg, Asya V.
通讯作者: Grinberg, Asya V.
DOI: 10.1093/cvr/cvm111
发表时间: 2008-05-01
影响因子: 10.8
作者:
Adya, Raghu;Tan, Bee K.;Randeva, Harpal S.
通讯作者: Randeva, Harpal S.
DOI: 10.1002/aja.1002030302
发表时间: 1995-07-01
影响因子: 2.5
作者:
KIMMEL, CB;BALLARD, WW;SCHILLING, TF
通讯作者: SCHILLING, TF